The Paris-based BrainVectis, a biotech developing gene therapies for Huntington’s disease and Alzheimer’s disease, has been acquired by the US clinical-stage gene therapy company AskBio.  AskBio’s gene therapy experience and manufacturing capacity will help to accelerate BrainVectis’ lead candidate for Huntington’s into phase I testing. In return, AskBio gets to expand its list of target […]